卡洛格司特甲与咪达唑仑、泼尼松龙或阿托伐他汀的健康成人潜在药物相互作用评价
本研究在88名健康志愿者中评估CYP3A4抑制剂卡洛格司特甲(960 mg,每日3次,共14天)与咪达唑仑、泼尼松龙或阿托伐他汀的相互作用。结果显示卡洛格司特甲与口服/静脉咪达唑仑及阿托伐他汀存在药代动力学相互作用,但与泼尼松龙无相互作用;卡洛格司特甲被归类为人体中度CYP3A4抑制剂。
要点
- 卡洛格司特甲与咪达唑仑、阿托伐他汀存在药代动力学相互作用。
- 卡洛格司特甲与泼尼松龙未见药代动力学相互作用。
- 卡洛格司特甲被归类为人体中度CYP3A4抑制剂。
核心结论
- 卡洛格司特甲被归类为人体中度CYP3A4抑制剂,可能增强经CYP3A4代谢药物的作用。
研究设计与样本
- 共88名健康志愿者口服卡洛格司特甲960 mg每日3次,持续14天。
- 在卡洛格司特甲给药前、合用期间及停药后分别给予单次口服或静脉咪达唑仑、口服泼尼松龙或口服阿托伐他汀。
- 当合用卡洛格司特甲(第14天)与给药前药代动力学参数几何均值比的90%置信区间在0.80至1.25之间时,判定无药代动力学相互作用。
主要发现
- 口服咪达唑仑给药前Cmax为30.9 ± 9.8 ng mL-1,AUC0-t为74.5 ± 21.9 ng h mL-1。
- 第14天与第-1天相比,咪达唑仑Cmax几何均值比为1.86(90% CI,1.64-2.11),AUC0-t几何均值比为3.07(90% CI,2.81-3.35),均未落在0.80-1.25范围内,提示存在药代动力学相互作用。
- 静脉咪达唑仑和阿托伐他汀也发现类似的药代动力学相互作用,但泼尼松龙未发现。
- 卡洛格司特甲对咪达唑仑和阿托伐他汀经CYP3A4介导代谢的抑制作用在停药后14天几乎消失。
关键数值与推荐
- 药代动力学相互作用判定标准:合用与给药前药代动力学参数几何均值比的90%置信区间在0.80至1.25之间视为无相互作用。
临床怎么用
- 使用卡洛格司特甲时应警惕经CYP3A4代谢的药物(如咪达唑仑、阿托伐他汀)可能因抑制作用而暴露增加。
- 与泼尼松龙合用时基于本研究未观察到药代动力学相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This study evaluated drug-drug interactions between the CYP3A4 inhibitor carotegrast methyl and the other CYP3A4 substrates, midazolam, atorvastatin and prednisolone. METHODS: A total of 88 healthy volunteers orally received carotegrast methyl 960 mg 3 times daily for 14 days. A single oral (5 mg) or intravenous (0.017 mg kg-1 ) midazolam, oral (5 mg) prednisolone or oral (10 mg) atorvastatin was administered before, with and after carotegrast methyl treatment. When the 90% confidence interval (CI) for the geometric mean ratios of the pharmacokinetic (PK) parameters with coadministration with carotegrast methyl (Day 14) to those before carotegrast methyl administration was between 0.80 and 1.25, no PK interaction were deemed. RESULTS: The Cmax and AUC0-t of oral midazolam before administration of carotegrast methyl were 30.9 ± 9.8 ng mL-1 and 74.5 ± 21.9 ng h mL-1 , respectively. The geometric mean ratio of the Cmax and AUC0-t of midazolam on Day 14 to those on Day -1 was 1.86 (90% CI, 1.64-2.11) and 3.07 (90% CI, 2.81-3.35), which did not fall within the range of 0.80-1.25, suggesting that carotegrast methyl had a PK interaction with midazolam. Similar PK interactions were found for intravenous midazolam and atorvastatin, but not for prednisolone. The inhibitory effect of carotegrast methyl on CYP3A4-mediated metabolism of midazolam and atorvastatin had almost disappeared by 14 days after the end of administration. CONCLUSION: Carotegrast methyl was classified as a moderate CYP3A4 inhibitor in humans. Carotegrast methyl might enhance the action of drugs that are metabolized by CYP3A4.
引用
- Matsuki S, Oikawa I, Koyama T, et al. Evaluation of the potential drug-drug interactions of carotegrast methyl with midazolam, prednisolone or atorvastatin in healthy adults. Br J Clin Pharmacol. 2023. PMID: 38030591. doi:10.1111/bcp.15979
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。